Nuwellis Adds Quality and Regulatory Director to Strengthen Cardiorenal Portfolio
Event summary
- Nuwellis appointed Brian Johnson as Director of Quality and Regulatory Affairs on September 16, 2026.
- Johnson brings 13 years of medical device quality and regulatory experience, including roles at Baxter/Vantive and ATL Medical.
- He will lead quality management, regulatory compliance, and cross-functional collaboration to support product development and commercialization.
- Nuwellis has also recently added expertise in medical affairs and engineering to bolster its capabilities.
The big picture
Nuwellis' appointment of Brian Johnson underscores its focus on strengthening quality and regulatory capabilities amid a push to expand its cardiorenal solutions. The move aligns with broader industry trends where medical technology companies are investing in governance and compliance to support product innovation and commercialization. Johnson's background in reducing customer complaints by 80% at ATL Medical suggests a potential for operational improvements at Nuwellis.
What we're watching
- Regulatory Execution
- How Johnson's leadership will impact Nuwellis' ability to navigate regulatory hurdles in its cardiorenal portfolio.
- Product Development Pace
- Whether the strengthened quality and regulatory team can accelerate the advancement of Nuwellis' multiple product programs.
- Commercialization Strategy
- The pace at which Nuwellis can integrate new expertise to enhance its commercialization efforts across acute and chronic care settings.